+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer



Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer



International Journal of Cancer 135(6): 1487-1496



Regorafenib, a novel multikinase inhibitor, has recently demonstrated overall survival benefits in metastatic colorectal cancer (CRC) patients. Our study aimed to gain further insight into the molecular mechanisms of regorafenib and to assess its potential in combination therapy. Regorafenib was tested alone and in combination with irinotecan in patient-derived (PD) CRC models and a murine CRC liver metastasis model. Mechanism of action was investigated using in vitro functional assays, immunohistochemistry and correlation with CRC-related oncogenes. Regorafenib demonstrated significant inhibition of growth-factor-mediated vascular endothelial growth factor receptor (VEGFR) 2 and VEGFR3 autophosphorylation, and intracellular VEGFR3 signaling in human umbilical vascular endothelial cells (HuVECs) and lymphatic endothelial cells (LECs), and also blocked migration of LECs. Furthermore, regorafenib inhibited proliferation in 19 of 25 human CRC cell lines and markedly slowed tumor growth in five of seven PD xenograft models. Combination of regorafenib with irinotecan significantly delayed tumor growth after extended treatment in four xenograft models. Reduced CD31 staining indicates that the antiangiogenic effects of regorafenib contribute to its antitumor activity. Finally, regorafenib significantly delayed disease progression in a murine CRC liver metastasis model by inhibiting the growth of established liver metastases and preventing the formation of new metastases in other organs. In addition, our results suggest that regorafenib displays antimetastatic activity, which may contribute to its efficacy in patients with metastatic CRC. Combination of regorafenib and irinotecan demonstrated an increased antitumor effect and could provide a future treatment option for CRC patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 055446596

Download citation: RISBibTeXText

PMID: 24347491

DOI: 10.1002/ijc.28669


Related references

Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer. Cancer Letters 386: 100-109, 2016

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International Journal of Cancer 129(1): 245-255, 2011

In vivo antitumor and antimetastatic activities of camptothecin encapsulated with N-trimethyl chitosan in a preclinical mouse model of liver cancer. Cancer Letters 297(1): 56-64, 2010

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma. Oncotarget 8(63): 107096-107108, 2018

Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models. Plos One 10(11): E0142612, 2016

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. Bmc Cancer 18(1): 136, 2018

The preclinical development of regorafenib for the treatment of colorectal cancer. Expert Opinion on Drug Discovery 9(9): 1087-1101, 2015

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget 7(31): 50290-50301, 2016

Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. Journal of Hepatology 56(3): 595-601, 2012

Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Letters 348(1-2): 20-28, 2014

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study. South Asian Journal of Cancer 8(1): 22-26, 2019

Antitumor and antimetastatic activities of chloroform extract of medicinal mushroom Cordyceps taii in mouse models. Bmc Complementary and Alternative Medicine 15: 216, 2016

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Research 72(3): 779-789, 2012

Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. Journal of the National Cancer Institute 88(8): 536-541, 1996

Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer. Biomedicine and PharmacoTherapy 64(9): 609-614, 2011